GH RESEARCH PLC
NASDAQ: GHRS (GH Research PLC)
Kemas kini terakhir: 6 jam lalu30.24
1.16 (3.99%)
| Penutupan Terdahulu | 29.08 |
| Buka | 29.25 |
| Jumlah Dagangan | 1,117,515 |
| Purata Dagangan (3B) | 287,917 |
| Modal Pasaran | 2,075,742,720 |
| Harga / Buku (P/B) | 5.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| EPS Cair (TTM) | -0.790 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.21% |
| Nisbah Semasa (MRQ) | 29.71 |
| Aliran Tunai Operasi (OCF TTM) | -41.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.93 M |
| Pulangan Atas Aset (ROA TTM) | -11.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | GH Research PLC | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.00 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.88% |
| % Dimiliki oleh Institusi | 68.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 31 Mar 2026 | 5,933,815 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 1,800,000 |
| Troluce Capital Advisors Llc | 31 Mar 2026 | 990,472 |
| 5Am Venture Management, Llc | 31 Mar 2026 | 572,665 |
| Squadron Capital Management Llc | 31 Mar 2026 | 325,000 |
| Foresite Capital Management Vi Llc | 31 Mar 2026 | 315,492 |
| Boothbay Fund Management, Llc | 31 Mar 2026 | 282,891 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |